Inhibition of cGMP-specific PDE5A and subsequently elevated cGMP have been used as the therapeutic strategies for improving tissue perfusion via dilation of arterioles in erectile dysfunction, pulmonary hypertension, ischemia/reperfusion injury, myocardial infarction, heart failure, and stroke (Francis et al., 2011). This evidence concerns the gene PDE5A and heart failure.